Q-omics provides the consensus-scored SULF2 profile across patient tissues and cancer cell-line models. SULF2 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, SULF2 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, SULF2 RNA expression shows 19,073 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight UVM, KIRC, and KIRP as cancer lineages where SULF2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SULF2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SULF2 survival associations across molecular data types. SULF2 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (9) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SULF2 RNA expression–survival associations across cancer types. High SULF2 expression shows unfavorable associations in UVM, ACC, BLCA and PAAD, but favorable associations in LGG and ESCA. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for SULF2 RNA expression.
This table summarizes SULF2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for SULF2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SULF2 shows lower tumor expression in UCEC and higher tumor expression in KIRC, HNSC, COAD, STAD and KIRP. The KIRC box plot shows higher SULF2 RNA expression in tumor versus normal tissue (log2 FC = +1.218, t-test p < 0.001).
This table shows molecular features associated with SULF2 in patient tissues and cancer cell lines. In patient samples, SULF2 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, SULF2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in BONE and SOFT_TISSUE.
